Caribou Biosciences
CRBUBerkeley, United States· Est. 2011
Caribou is a clinical-stage biopharmaceutical company focused on developing genome-edited allogeneic cell therapies for devastating human diseases.
CRBU · Stock Price
USD 1.820.05 (-2.67%)
Market Cap: $184.6M
Historical price data
About
Caribou is a clinical-stage biopharmaceutical company focused on developing genome-edited allogeneic cell therapies for devastating human diseases.
Cell & Gene Therapy
Funding History
4Total raised:$460.2M
IPO$304.2MJul 22, 2021
Series C$115MDec 15, 2020
Series B$30MOct 15, 2017
Series A$11MMay 15, 2015